Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

AZO GANTRISIN

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

Standard Dose
50MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview AZO GANTRISIN is listed in Drugs@FDA under application 019358 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE Form and strength TABLET;ORAL - 50MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ROCHE Submission history Latest submission status date: 1990-08-31 00:00:00.

Structured Monograph

Clinical summary

Approval overview AZO GANTRISIN is listed in Drugs@FDA under application 019358 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE Form and strength TABLET;ORAL - 50MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ROCHE Submission history Latest submission status date: 1990-08-31 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
AZO GANTRISIN (PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE) | Drug Monograph | MedicHelpline